The IDIBELL spin-off, created in 2017 and based in L’Hospitalet de Llobregat, is one of the 36 companies selected from among the 1,406 applications received in the EIC Accelerator call of the Horizon 2020 programme.
The chemoresistance group of IDIBELL and ICO’s ProCURE Program, led by Alberto Villanueva, has transferred its experience in generating orthotopic mouse models in adult patients to the pediatric field.
People who sleep fewer hours show less consistency in the neural patterns of the repetitions, showing less memory retention.
A study with the participation of IDIBELL adds complete information on the complications and prognosis of the first 4,035 patients with COVID-19 in the country.
A team from the IDIBELL-ICO Hereditary Cancer group has studied more than 2,800 patients with a possible hereditary cancer to determine the frequency of pathogenic mutations in the corrective region of two polymerases.
Identifying these mutations can facilitate the early diagnosis and the personalized treatment of these patients.
Regenerative medicine scientists at IDIBELL in collaboration with partners at Ulm University (Germany) have demonstrated that inhibition of Cdc42 with CASIN can pharmacologically extend lifespan.
